Novavax (NVAX) delivered earnings and revenue surprises of -0.89% and 40.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -80% and 96.75%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Celldex (CLDX) delivered earnings and revenue surprises of 1.59% and 157.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ: TFFP). Such...
TFFP earnings call for the period ending June 30, 2022.
The mean of analysts' price targets for TFF Pharmaceuticals, Inc. (TFFP) points to a 233.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement...
FORT WORTH, Texas, May 20, 2022 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on...
TFFP earnings call for the period ending March 31, 2022.
TFF Pharmaceuticals, Inc. (TFFP) delivered earnings and revenue surprises of 13.16% and 33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Announced Collaboration with Catalent to Further Expand Thin Film Freezing Applications with a Focus on Biologic Drug Development Announced Second CRADA...